XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

BACKGROUND: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer. METHODS: Patients previously untreated for metastatic disease were randomized in: group A (irinotecan, capecitabine, bevacizumab, eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Pectasides, Dimitrios, Papaxoinis, George, Kalogeras, Konstantine T, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Makatsoris, Thomas, Samantas, Epaminondas, Varthalitis, Ioannis, Papakostas, Pavlos, Nikitas, Nikitas, Papandreou, Christos N, Pentheroudakis, George, Timotheadou, Eleni, Koutras, Angelos, Sgouros, Joseph, Bafaloukos, Dimitrios, Klouvas, George, Economopoulos, Theofanis, Syrigos, Konstantinos N, Fountzilas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466131/
https://www.ncbi.nlm.nih.gov/pubmed/22748098
http://dx.doi.org/10.1186/1471-2407-12-271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466131/
https://www.ncbi.nlm.nih.gov/pubmed/22748098
http://dx.doi.org/10.1186/1471-2407-12-271

Ejemplares similares